Werewolf Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Werewolf Therapeutics Inc 's ROA in the second quarter of 2026?
Werewolf Therapeutics Inc recorded a cumulative net loss of $-35 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -59.88%.

However, within the Healthcare sector 611 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4155, from total ROA ranking in the first quarter of 2026 at 4798.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-73.91 %	-45.89 %	-45.33 %	-40.84 %	-36.98 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-35	-56	-61	-73	-73
Return On Assets (TTM)	-59.88 %	-75.12 %	-69.75 %	-71.7 %	-63.42 %
HOWL's Total Ranking	# 4155	# 4798	# 4216	# 4210	# 4214
Total Assets (TTM) in million	24	58	69	80	93
Seq. Total Assets Change	-58.37 %	-16.39 %	-12.85 %	-13.98 %	-13.68 %
Seq. Net Income Change	-	-	-	-	-

HOWL's 5 Years Annual ROA >> Back to HOWL Management Effectiveness >> Compare HOWL ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 274
Sector	# 612
Overall	# 3989

Return On Assets Statistics
High	Average	Low
-20.43 %	-41.74 %	-75.12 %
(Dec 31 2023)		(Mar 31 2026)

Financial Statements
Werewolf Therapeutics Inc 's Assets	$ 24 million	HOWL's Balance sheet
Werewolf Therapeutics Inc 's Income	$ 4 million	Quarterly HOWL's Income Statement
HOWL's Income by Division		See HOWL's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-45.33 %	-14.43 %	-2.54 %	-8.31 %	-
Total Assets in million	69	127	148	152	166
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-61	-71	-37	-54	-50
Annual Return On Assets	-87.64 %	-55.55 %	-25.19 %	-35.36 %	-30.11 %

HOWL's 5 Years Annual ROA >> Back to HOWL Management Effectiveness >> Compare HOWL ROA to its Competitors

More Return On Assets Ratios
HOWL's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
HOWL's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for HOWL's Competitors
Subscribers only: Roa for Werewolf Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for HOWL's Customers

You may also want to know
HOWL's Roi	HOWL's Inventory Turnover Ratio	HOWL's Growth Rates	HOWL's Dividend Comparisons
	HOWL's Profitability Ratios	HOWL's Asset Turnover Ratio	HOWL's Dividend Growth
HOWL's Roe	HOWL's Valuation Ratios	HOWL's Financial Strength Ratios	HOWL's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-30T20:41:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.